Progress in Transgene's tumor-targeting mission

French biotech Transgene (Euronext Paris: TNG) has announced the publication of two articles highlighting the potential of its virus-based immunotherapies for the treatment of solid tumors.

The company’s therapeutic vaccine TG4001, administered as a single agent, demonstrated statistically-significant curative activity at 30 months in a randomized Phase IIb trial in precancerous HPV-induced lesions.

These results are highly supportive of the ongoing development of TG4001 in combination with avelumab, a drug marketed as Bavencio, in HPV-positive cancers, including head and neck carcinomas, for which efficacy data are expected later this year.